Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (OTCPK:AZNCF)

Publication of Final Terms - XS1402945601

UK Regulatory news services, from the LSE May 3, 2016

BEVESPI AEROSPHERE(TM) Approved by the US FDA for Patients With COPD

Marketwired April 25, 2016

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

PR Newswire April 21, 2016

AstraZeneca Presents DNA Damage Response Science at the AACR 2016 Annual Meeting

Business Wire April 18, 2016

Allergan Reinforces Commitment to Anti-Infective Innovation with 20 Abstracts Highlighted at ECCMID 2016

PR Newswire April 8, 2016

PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure

Benzinga.com  April 6, 2016

BRILINTA Preferred Over clopidogrel In Updated American College of Cardiology and American Heart Association Guideline in Acute Coronary Syndrome

Business Wire March 31, 2016

FDA Approves New Indication for FASLODEX® (fulvestrant)

Business Wire March 2, 2016

UPDATE: AstraZeneca Release Was Posted Earlier To Day

Press Releases February 17, 2016

Durvalumab Granted Breakthrough Therapy Designation By US FDA

Press Releases February 17, 2016

FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO® (ceftaroline fosamil)

Press Releases February 16, 2016

Looking Into the Price Movements - Consensus Reports on Astrazeneca, Abbott Laboratories, Keurig Green Mountain and Time Warner Cable

Accesswire February 8, 2016

Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration

Business Wire January 11, 2016

These Currency Hedged ETFs Could Enjoy 2016

Benzinga.com  December 7, 2015

Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology

Business Wire December 7, 2015

PEGASUS-TIMI 54 Sub-Analysis Outlines Long-Term Tolerability Data for BRILINTA

Business Wire November 10, 2015

AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients

Business Wire November 9, 2015

ZS PHARMA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

PR Newswire November 6, 2015

FDA Advisory Committee Recommends the Approval of Lesinurad for Gout Patients

Business Wire October 23, 2015

Phase 2 Data for Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Show Anemia Correction in Incident Dialysis Chronic Kidney Disease Patients Regardless of Iron Repletion Status, Iron Supplementation Regimen, or Dialysis Modality

GlobeNewswire October 22, 2015